ReviewFrontiers in immunology2020
Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Long term cardiometabolic outcomes in COVID positive patients.Journal of public health research · 2026Review
- Physiological Basis for Using Vitamin D to Improve Health.Biomedicines · 2023Article
- Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review.Biomedicines · 2023Review
- Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now.Frontiers in pharmacology · 2023Review
- Aptamers-Diagnostic and Therapeutic Solution in SARS-CoV-2.International journal of molecular sciences · 2022Review
- Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.American journal of translational research · 2022Article
- Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail?Frontiers in cardiovascular medicine · 2022Article
- Vaccine design and delivery approaches for COVID-19.International immunopharmacology · 2021Review
- Evaluating characteristics associated with the mortality among invasive ventilation COIVD -19 patients.Annals of medicine and surgery (2012) · 2021Article
- A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.EMBO molecular medicine · 2021Review
- Transcriptome of nasopharyngeal samples from COVID-19 patients and a comparative analysis with other SARS-CoV-2 infection models reveal disparate host responses against SARS-CoV-2.Journal of translational medicine · 2021Article
- Cinnamon: A Promising Natural Product Against COVID-19.Advances in experimental medicine and biology · 2021Article
- On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers.Frontiers in immunology · 2021Article
- Case Report: Acute Intracardiac Thrombosis in Children With Coronavirus Disease 2019 (COVID-19).Frontiers in pediatrics · 2021Article
- Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective.Archives of pharmacal research · 2021Review
- Mining the past to treat the present, ever mindful of the future: Low-dose radiotherapy and COVID-19 pneumonia.Cancer · 2020Article
- Nucleic acid-based therapy for coronavirus disease 2019.Heliyon · 2020Review
- Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.Frontiers in pharmacology · 2020Review
- Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In December 2019, following a cluster of pneumonia cases in China caused by a novel coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection disseminated worldwide and, on March 11th, 2020, the World Health Organization officially declared the pandemic of the relevant disease named coronavirus disease 2019 (COVID-19). In Europe, Italy was the first country facing a true health policy emergency, and, as at 6.00 p.m. on May 2nd, 2020, there have been more than 209,300 confirmed cases of COVID-19. Due to the increasing number of patients experiencing a severe outcome, global scientific efforts are ongoing to find the most appropriate treatment. The usefulness of specific anti-rheumatic drugs came out as a promising treatment option together with antiviral drugs, anticoagulants, and symptomatic and respiratory support. For this reason, we feel a duty to share our experience and our knowledge on the use of these drugs in the immune-rheumatologic field, providing in this review the rationale for their use in the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.